To achieve these ends, the FDA will use computer modeling and artificial intelligence (AI) to predict a drug’s behavior and promote the use of lab-grown human organoids (tiny, self-organized three-dimensional tissue cultures derived from stem cells) and organ-on-a-chip systems that mimic human organs to test drug safety.

The move comes after lawmakers sought to force the agency to update regulations that would allow alternatives to animal testing.

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that there are “more effective,